604 related articles for article (PubMed ID: 31432388)
21. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
Kramer GM; Frings V; Hoetjes N; Hoekstra OS; Smit EF; de Langen AJ; Boellaard R
J Nucl Med; 2016 Sep; 57(9):1343-9. PubMed ID: 27103020
[TBL] [Abstract][Full Text] [Related]
22. Correlation of (18)F-FDG avid volumes on pre-radiation therapy and post-radiation therapy FDG PET scans in recurrent lung cancer.
Shusharina N; Cho J; Sharp GC; Choi NC
Int J Radiat Oncol Biol Phys; 2014 May; 89(1):137-44. PubMed ID: 24725696
[TBL] [Abstract][Full Text] [Related]
23. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer.
Nehmeh SA; Lee NY; Schröder H; Squire O; Zanzonico PB; Erdi YE; Greco C; Mageras G; Pham HS; Larson SM; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):235-42. PubMed ID: 18086391
[TBL] [Abstract][Full Text] [Related]
24. Radiotherapy boost in patients with hypoxic lesions identified by
Vera P; Mihailescu SD; Lequesne J; Modzelewski R; Bohn P; Hapdey S; Pépin LF; Dubray B; Chaumet-Riffaud P; Decazes P; Thureau S;
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1448-1456. PubMed ID: 30868230
[TBL] [Abstract][Full Text] [Related]
25. To Explore a Representative Hypoxic Parameter to Predict the Treatment Response and Prognosis Obtained by [
Li L; Wei Y; Huang Y; Yu Q; Liu W; Zhao S; Zheng J; Lu H; Yu J; Yuan S
Mol Imaging Biol; 2018 Dec; 20(6):1061-1067. PubMed ID: 29623510
[TBL] [Abstract][Full Text] [Related]
26. 18F-FDG PET definition of gross tumor volume for radiotherapy of lung cancer: is the tumor uptake value-based approach appropriate for lymph node delineation?
Rodríguez N; Sanz X; Trampal C; Foro P; Reig A; Lacruz M; Membrive I; Lozano J; Quera J; Algara M
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):659-66. PubMed ID: 20133071
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
28. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients.
Bollineni VR; Kerner GS; Pruim J; Steenbakkers RJ; Wiegman EM; Koole MJ; de Groot EH; Willemsen AT; Luurtsema G; Widder J; Groen HJ; Langendijk JA
J Nucl Med; 2013 Aug; 54(8):1175-80. PubMed ID: 23753185
[TBL] [Abstract][Full Text] [Related]
29. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
[TBL] [Abstract][Full Text] [Related]
30. Necrosis on pre-radiotherapy 18F-FDG PET/CT is a predictor for complete metabolic response in patients with non-small cell lung cancer.
Eren G; Kupik O
Medicine (Baltimore); 2022 May; 101(20):e29227. PubMed ID: 35608423
[TBL] [Abstract][Full Text] [Related]
31. Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET.
Norikane T; Yamamoto Y; Maeda Y; Kudomi N; Matsunaga T; Haba R; Iwasaki A; Hoshikawa H; Nishiyama Y
Nucl Med Commun; 2014 Jan; 35(1):30-5. PubMed ID: 24121312
[TBL] [Abstract][Full Text] [Related]
32. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
[TBL] [Abstract][Full Text] [Related]
33. Delineation of lung cancer with FDG PET/CT during radiation therapy.
Ganem J; Thureau S; Gardin I; Modzelewski R; Hapdey S; Vera P
Radiat Oncol; 2018 Nov; 13(1):219. PubMed ID: 30419929
[TBL] [Abstract][Full Text] [Related]
34. Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation.
Aerts HJ; Bussink J; Oyen WJ; van Elmpt W; Folgering AM; Emans D; Velders M; Lambin P; De Ruysscher D
Lung Cancer; 2012 Jan; 75(1):73-6. PubMed ID: 21782272
[TBL] [Abstract][Full Text] [Related]
35. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
Dong X; Wu P; Sun X; Li W; Wan H; Yu J; Xing L
J Med Imaging Radiat Oncol; 2015 Jun; 59(3):338-45. PubMed ID: 25708154
[TBL] [Abstract][Full Text] [Related]
36. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.
Rajendran JG; Wilson DC; Conrad EU; Peterson LM; Bruckner JD; Rasey JS; Chin LK; Hofstrand PD; Grierson JR; Eary JF; Krohn KA
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):695-704. PubMed ID: 12632200
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Tumor Uptake Heterogeneity Characterization Between Static and Parametric 18F-FDG PET Images in Non-Small Cell Lung Cancer.
Tixier F; Vriens D; Cheze-Le Rest C; Hatt M; Disselhorst JA; Oyen WJ; de Geus-Oei LF; Visser EP; Visvikis D
J Nucl Med; 2016 Jul; 57(7):1033-9. PubMed ID: 26966161
[TBL] [Abstract][Full Text] [Related]
38. Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy.
Aoki M; Akimoto H; Sato M; Hirose K; Kawaguchi H; Hatayama Y; Seino H; Kakehata S; Tsushima F; Fujita H; Fujita T; Fujioka I; Tanaka M; Miura H; Ono S; Takai Y
J Radiat Res; 2016 Sep; 57(5):533-540. PubMed ID: 27296251
[TBL] [Abstract][Full Text] [Related]
39. Biological image-guided radiotherapy in rectal cancer: is there a role for FMISO or FLT, next to FDG?
Roels S; Slagmolen P; Nuyts J; Lee JA; Loeckx D; Maes F; Stroobants S; Penninckx F; Haustermans K
Acta Oncol; 2008; 47(7):1237-48. PubMed ID: 18654902
[TBL] [Abstract][Full Text] [Related]
40. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan.
Aerts HJ; van Baardwijk AA; Petit SF; Offermann C; Loon Jv; Houben R; Dingemans AM; Wanders R; Boersma L; Borger J; Bootsma G; Geraedts W; Pitz C; Simons J; Wouters BG; Oellers M; Lambin P; Bosmans G; Dekker AL; De Ruysscher D
Radiother Oncol; 2009 Jun; 91(3):386-92. PubMed ID: 19329207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
